Ascendis Pharma A/S $ASND Shares Newly Bought by Inspire Investing LLC

Key Points

• Inspire Investing acquired 10,428 Ascendis Pharma shares during the third quarter, valued at approximately $2.38 million. Several other institutional investors also initiated or increased positions.
• Wall Street remains broadly positive, with 19 analysts rating the stock Buy and one assigning a Hold; the consensus rating is “Moderate Buy” with an average price target of $309.26.
• Ascendis Pharma shares opened at $243.37, while the company’s latest results showed $387.22 million in revenue but earnings of $1.03 per share, below the $1.71 consensus estimate.

Inspire Investing LLC acquired a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 10,428 shares of the biotechnology company's stock, valued at approximately $2,376,000.

Several other large investors also recently added to or reduced their stakes in the stock. Crossmark Global Holdings Inc. bought a new position in Ascendis Pharma A/S in the 3rd quarter worth about $377,000. Sowell Financial Services LLC bought a new stake in shares of Ascendis Pharma A/S during the third quarter valued at approximately $202,000. Nisa Investment Advisors LLC raised its stake in shares of Ascendis Pharma A/S by 28,468.4% during the third quarter. Nisa Investment Advisors LLC now owns 5,428 shares of the biotechnology company's stock valued at $1,237,000 after acquiring an additional 5,409 shares in the last quarter. Diversify Advisory Services LLC boosted its holdings in shares of Ascendis Pharma A/S by 10.0% in the third quarter. Diversify Advisory Services LLC now owns 12,299 shares of the biotechnology company's stock valued at $2,787,000 after purchasing an additional 1,118 shares during the period. Finally, New Wave Wealth Advisors LLC boosted its holdings in shares of Ascendis Pharma A/S by 7.8% in the third quarter. New Wave Wealth Advisors LLC now owns 5,189 shares of the biotechnology company's stock valued at $1,158,000 after purchasing an additional 375 shares during the period.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. Cantor Fitzgerald reissued an "overweight" rating and issued a $300.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, September 25th. Citigroup reaffirmed a "buy" rating on shares of Ascendis Pharma A/S in a research report on Monday. UBS Group reiterated a "buy" rating and issued a $269.00 target price (down from $307.00) on shares of Ascendis Pharma A/S in a report on Thursday, October 15th. BMO Capital Markets reissued an "outperform" rating on shares of Ascendis Pharma A/S in a research report on Thursday, September 10th. Finally, Raymond James Financial downgraded Ascendis Pharma A/S from a "strong-buy" rating to an "outperform" rating and set a $287.00 price target on the stock. in a research report on Tuesday, September 15th. Nineteen research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $309.26.

Ascendis Pharma A/S Stock Performance

NASDAQ:ASND opened at $243.37 on Monday. Ascendis Pharma A/S has a one year low of $188.07 and a one year high of $282.15. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.32 and a current ratio of 2.99. The firm has a market cap of $15.18 billion, a P/E ratio of 18.88 and a beta of 0.38. The firm has a 50-day simple moving average of $243.04 and a 200-day simple moving average of $242.90.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share for the quarter, missing the consensus estimate of $1.71 by ($0.68). Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. The business had revenue of $387.22 million during the quarter, compared to analysts' expectations of $376.75 million. Equities analysts anticipate that Ascendis Pharma A/S will post 3.43 EPS for the current fiscal year.

Insider Activity at Ascendis Pharma A/S

In other Ascendis Pharma A/S news, Director Jean-Jacques Bienaimé acquired 2,000 shares of Ascendis Pharma A/S stock in a transaction that occurred on Friday, August 14th. The stock was bought at an average price of $246.33 per share, with a total value of $492,660.00. Following the completion of the purchase, the director directly owned 2,900 shares of the company's stock, valued at approximately $714,357. This represents a 222.22% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Mads Bodenhoff sold 3,000 shares of the business's stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total transaction of $810,570.00. Following the completion of the transaction, the senior vice president directly owned 3,000 shares of the company's stock, valued at $810,570. This trade represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 40.00% of the company's stock.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company uses its proprietary TransCon technology platform to design long-acting medicines intended to improve treatment convenience, maintain controlled drug exposure, and address unmet medical needs.

Its commercial products include SKYTROFA (lonape­gsomatropin-tcgd), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a once-daily therapy for adults with hypoparathyroidism.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.